Allergan PLC said early Wednesday that it plans to buy privately-held medical device company Keller Medical Inc., which developed a funnel used during breast surgery procedures.
The Keller Funnel, which helps plastic surgeons guide implants into the surgical pocket and reduces the risk of implant contamination, is “a natural complement to our world-class plastic surgery and regenerative medicine business,” said Senior Vice President of Medical Aesthetics David Moatazedi.
Plastic surgery and cosmetics has become a key business area for Allergan, with its aesthetics business — which includes Botox among other products — seen as one of its key assets. Allergan spent nearly $2.5 billion earlier this year to buy body-contouring company Zeltiq Aesthetics. Allergan shares were not active in premarket trade. Shares have dropped 4.7% over the last three months, compared with a 2.6% rise in the S&P 500.
By Emma Court
Source: Market Watch
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
